Chongqing Pharscin Pharmaceutical (SHE:002907) obtained the re-registration from China's drug regulator for its gabexate mesylate active pharmaceutical ingredient.
The API is used in the manufacture of gabexate mesylate, an emergency medication for acute pancreatitis, according to a Wednesday filing with the Shenzhen bourse.
Shares of the pharmaceutical company closed 1% lower Wednesday.